US2021106722A1PendingUtilityA1

Compositions comprising low molecular weight silk fibroin fragments and plasticizers

Assignee: SOFREGEN MEDICAL INCPriority: Oct 31, 2016Filed: Oct 27, 2020Published: Apr 15, 2021
Est. expiryOct 31, 2036(~10.3 yrs left)· nominal 20-yr term from priority
C08L 5/08A61L 27/56C08L 89/00A61L 27/26A61L 2400/06A61L 27/227A61L 2430/34C08K 5/0016C08K 5/053A61L 27/502
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Various aspects described herein relate to compositions comprising silk fibroin fragments with particular characteristics and/or properties as well as methods of making and using the same.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A solution for forming a scaffold, the solution comprising silk fibroin fragments, the silk fibroin fragments having a weight average molecular weight ranging from about 100 kDa to about 160 kDa; wherein the solution for forming the scaffold exhibits a glass transition temperature of equal to or less than about −15° C., and wherein the solution for forming the scaffold is sterile. 
     
     
         2 . The solution of  claim 1 , wherein the solution further comprises an alcohol and/or a polyol. 
     
     
         3 . A silk fibroin particle comprising silk fibroin fragments, wherein the silk fibroin fragments have a weight average molecular weight ranging from about 100 kDa to about 160 kDa, and wherein the silk fibroin particle comprises a porous structure characterized by interconnected pores having an average circle equivalent diameter of about 5 μm to about 60 μm and having an aspect ratio of about 1.0 to about 3.0, and wherein the silk fibroin particle has an aspect ratio of about 1 to about 3. 
     
     
         4 . The silk fibroin particle of  claim 3 , wherein the silk fibroin particle is formed from a lyophilized scaffold. 
     
     
         5 . The solution of  claim 1 , wherein the solution has been sterilized by vacuum filtration. 
     
     
         6 . The solution of  claim 1 , wherein the silk fibroin fragments have a weight average molecular weight ranging from about 130 kDa to about 160 kDa. 
     
     
         7 . The solution of  claim 1 , wherein no more than about 5% of the total number of the silk fibroin fragments have a molecular weight of about 200 kDa or higher. 
     
     
         8 . The solution of  claim 1 , wherein at least about 60% of the total number of silk fibroin fragments have a molecular weight of about 30 kDa to about 170 kDa. 
     
     
         9 . A silk fibroin scaffold formed from the solution of  claim 1 . 
     
     
         10 . A silk fibroin particle formed from the scaffold of  claim 9 . 
     
     
         11 . The silk fibroin particle of  claim 3 , wherein the silk fibroin particle is formed from a sterile solution. 
     
     
         12 . The silk fibroin particle of  claim 11 , wherein the sterile solution has a glass transition temperature of equal to or less than about −15° C. 
     
     
         13 . The silk fibroin particle of  claim 11 , wherein the sterile solution has been sterilized by vacuum filtration. 
     
     
         14 . The silk fibroin particle of  claim 3 , wherein the silk fibroin fragments have a weight average molecular weight ranging from about 130 kDa to about 160 kDa. 
     
     
         15 . The silk fibroin particle of  claim 3 , wherein the silk fibroin particle is formed from a sterile solution, and wherein the sterile solution has a glass transition temperature of equal to or less than about −15° C. 
     
     
         16 . The silk fibroin particle of  claim 15 , wherein the sterile solution has been sterilized by vacuum filtration.

Join the waitlist — get patent alerts

Track US2021106722A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.